Psychiatry & Neurology Doctors in Edgewood, KY Accepting Medicare

7 Psychiatry & Neurology doctors found. Showing 1 - 7

Dr. Mark Joseph Barbara, MD Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 200 Medical Village Dr, Edgewood, KY 41017 Phone: 859-301-5900    Fax: 859-301-5940

Lalanthica Vilashini Yogendran, M.D., M.P.H. Psychiatry & Neurology - Neurology Medicare: Medicare Enrolled Practice Location: 1 Medical Village Dr, Edgewood, KY 41017 Phone: 859-301-4000    Fax: 859-301-2607

Richard Curry Iii, MD Psychiatry & Neurology - Neurology Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Village Dr, Edgewood, KY 41017 Phone: 859-301-2237    Fax: 859-344-5552

Mr. Bahram Ziaie, M.D. Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 20 Medical Village Dr., Suite 107, Edgewood, KY 41017 Phone: 859-344-8333    Fax: 859-344-0052

Dr. Robert E Albright Jr., MD Psychiatry & Neurology - Neurology Medicare: Medicare Enrolled Practice Location: 1 Medical Village Dr, Edgewood, KY 41017 Phone: 859-301-2237    Fax: 859-578-5960

Dr. Nelson Tauro, M.D. Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 200 Medical Village Dr, St Elizabeth Physicians Behavioral Health, Edgewood, KY 41017 Phone: 859-301-5901    Fax: 859-301-5940

Dr. Lea Hayag-thomas, MD Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 200 Medical Village Dr, Edgewood, KY 41017 Phone: 859-301-5900    Fax: 859-301-5940

News Archive

Damon Runyon creates new award to increase number of physician-scientists

Physician-scientists are crucial to moving scientific discoveries from the lab to patients, but their numbers have been dwindling just when they are needed most, particularly in cancer research, as the number of cancer cases is projected to increase by 45 percent in the next fifteen years and elevate cancer to the leading cause of death in America.

Repros Therapeutics announces response to FDA critique on proposed Phase II Androxal study

Repros Therapeutics Inc. today announced that the Company is sending a reply to the FDA's Division of Metabolism and Endocrinology Products following the Company's receipt of FDA's comments on the proposed Phase II study of Androxal® (enclomiphene) in the treatment of Type II diabetes under Repros' open IND. On February 2, 2010 the Company announced that Repros received confirmation from the Agency that the new IND is effective.

Viewpoints: Shortages of drugs persist; number of Medicare doctors is growing; Obamacare undermines health savings accounts

As was the case during the last debt-ceiling debacle, in 2011, playing politics with the nation's creditworthiness is irresponsible and unnecessary. Leave aside the ObamaCare obsession, because Republicans have zero chance of persuading the president to kill one of his defining achievements.

New trial to assist patients with severe and enduring mental health illnesses

The pandemic has made it more difficult for the 430,000+ Australians living with severe mental illnesses who are highly vulnerable to acute illness relapses when their habitual routines and standard health care arrangements are disrupted.

Read more Medical News

› Verified 2 days ago